Michael Scholle has served as Chief Operating Officer since January 2019 and is also a co-founder of SAMDI Tech. He previously held positions as Vice President of Operations and Technology and Director at the company from 2011-2018. He brings more than 20 years of experience in building biotech companies, commercializing technology platforms, high throughput drug discovery, MALDI TOF mass spectrometry, biochemistry, molecular biology, and antibody discovery.
Prior to SAMDI Tech, Scholle held various scientific positions at Integrated Genomics Inc, Argonne National Laboratory, and Amunix Inc. At Amunix, he was a founding scientist and played a key role in the development of XTEN, a half-life enhancing technology. XTEN technology was taken public by Versartis with an IPO in 2013. Scholle has served on the Board of Directors at Amunix and now Tango Biosciences. He has authored over 20 peer-reviewed articles published in scientific and business journals. Scholle has a master’s degree in biology from Northern Illinois University and an MBA from Roosevelt University-Chicago.